



Investor Update No.22 January – March 2011



Forward looking statements

To the extent that this presentation contains any forecasts, projections or other forward looking statements, they are based upon current expectations and are subject to uncertainty and contingencies, many of which are outside the control of CathRx. Actual performance, events, results or outcomes may differ for a variety of reasons. Furthermore, the assumptions underlying the forward looking statements could prove inaccurate or incorrect. Therefore, there can be no assurance actual results, performance or achievements will be as stated. The reliance that a recipient of this presentation places on any statement, forecast, projection or assumption is a matter for their own commercial judgment. This presentation has been prepared in good faith and with due care. However, none of CathRx or its directors, employees or advisers warrant or represent the accuracy or completeness of the information contained in this presentation.



Strategic program update

- Meetings with several potential partners to explore a technology deal are progressing as well as we had expected.
- Irrigated ablation catheter now approved, variable loop pending submission
- The ablation catheter demonstrates CathRx's capacity to develop and have approved both therapeutic and diagnostic catheters.
- The variable loop catheter will demonstrate CathRx's capacity to develop reprocessable catheters in this sector where that has never been done before.

	Strategy	Status	Comments
1	Execute partnership agreement	Europe Completed	<ul style="list-style-type: none"> ▪ Executed partnership agreement with Pioneer ▪ CXD to receive revenue on the sale and re-use of its catheter devices and components ▪ Commenced trade in Europe
2	Future partnerships	Next 3-6 months	<ul style="list-style-type: none"> ▪ Meetings with several potential partners ▪ Exploring technology deal ▪ Oppenheimer appointed to manage the process
3	Product pipeline	Next 3-6 months	<ul style="list-style-type: none"> ▪ First irrigated ablation catheter now approved ▪ Clinical data procedures commenced– variable loop catheter + CS catheter ▪ Prove advanced AF technology platform



Financial snapshot (unaudited)

Income Statement \$'000	Q3 2011 31 March 2011	Q3 2010 31 March 2010
Revenue	0	27
Gross Profit	0	(8)
Total Expenses	(2,090)	(2,464)
Net Loss	(2,090)	(2,472)
Balance Sheet \$'000	31 March 2011	31 March 2010
Cash	6,482	2,229
Other assets	5,488	6,945
Liabilities	1,432	1,272
Net Assets	10,538	7,902
Cash flow \$'000	Q3 2011 31 March 2011	Q3 2010 31 March 2010
Cash flows from operating activities	(1,803)	(2,745)
Cash flows from investing activities	(56)	(65)
Cash flows from financing and other activities	27	24
Net increase / (decrease) in cash held	(1,832)	(2,786)